Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at…
Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher…
Read More...
Read More...